Antibiotics

Ampicillin/Sulbactam

Ampicillin/sulbactam is a beta-lactam/beta lactamase inhibitor combination antibiotic. It has activity against MSSA, streptococci, enterococci, and anaerobes. It also has activity against enteric Gram-negative organisms. However, an increasing number of *E. coli* and *Proteus* spp. are now resistant. Because of this, its use for empiric treatment of intraabdominal infections is no longer advised unless pathogen susceptibilities are known.

**Acceptable uses**
- Treatment of human or animal bites if parenteral therapy is needed.
- Treatment of oral infections
- Treatment of lung abscess
- Treatment of culture-negative endocarditis (ID consult advised)
- Treatment of multi-drug resistant (MDR) *Acinetobacter* spp. (ID consult advised)
- Treatment of uncomplicated vancomycin-resistant enterococcal UTIs (ampicillin can be used without sulbactam in this case)

**Unacceptable uses**
- Empiric treatment of biliary tract infections, diverticulitis, or secondary/peritonitis/GI perforation. Use should be limited to infections that are proven to be susceptible.

**Dose**
1.5 - 3 g IV q6-8h (higher doses may be used for infections due to MDR *Acinetobacter* spp.)

**Ceftaroline**

**ID consult or ASP approval is required**

Ceftaroline is a new broad-spectrum cephalosporin with a spectrum of activity similar to ceftiraxone, but with activity against MRSA. Ceftaroline demonstrates *in vitro* activity against resistant Gram-positive pathogens including methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant *Enterococcus faecalis* (not *E. faecium*) as well as common Gram-negative pathogens such as *Haemophilus influenzae* and enteric Gram-negative bacilli, such as *Escherichia coli* and *Klebsiella pneumoniae*. Ceftaroline does not have activity against extended-spectrum beta-lactamase producing or AmpCderepressed Enterobacteriaceae or most nonfermentative Gram-negative bacilli, such as *Pseudomonas* and *Acinetobacter*. Ceftaroline demonstrates limited activity against anaerobes such as *Bacteroides fragilis*.

Ceftaroline is FDA-approved for treatment of skin/skin structure infections (including cases caused by MRSA) and community-acquired pneumonia (including cases caused by penicillin-resistant *S. pneumoniae*). While there are animal models and case reports of successful use of ceftaroline for the treatment of osteomyelitis, bacteremia, and endocarditis, ceftaroline is not yet FDA-approved for these indications.

**Acceptable uses**
- Complicated skin/skin structure infections*
- Community-acquired bacterial pneumonia*
Salvage for sustained MRSA bacteremia/endocarditis*

*All must meet the following criteria for use:
- Where MRSA is highly suspected or documented AND vancomycin is not an option
- MRSA with a vancomycin MIC ≥ 2
- Sustained difficulty in achieving appropriate vancomycin levels despite clinical pharmacy assistance with pharmacokinetics or where a vancomycin continuous infusion is not an option.
- Treatment of mixed infections, requires documentation of susceptibility

Unacceptable uses
- Selected over vancomycin in patients with renal failure solely as a reason to avoid vancomycin
- Selected solely for convenience

Dose
- 600 mg IV q12h
- MRSA bloodstream infections/endocarditis may require higher dosing and should only be undertaken with Infectious Diseases or Antimicrobial Stewardship Program input.

Toxicity
- Similar to other cephalosporins, generally well-tolerated.

Colistin

Formal ID consultation or ASP approval is required

Colistin is a polymyxin antibiotic. It has activity against most Gram-negative bacilli, including many multi-drug resistant *Enterobacteriaceae, Acinetobacter* spp. and *P. aeruginosa*. Notably, it is not active against the following Gram-negative genera: *Proteus, Serratia, Providencia, Burkholderia*, as well as Gram-negative cocci, Gram-positive organisms, or anaerobes.

Acceptable uses
- Management of infections due to multi-drug resistant *Enterobacteriaceae, Acinetobacter*, and *Pseudomonas* on a case-by-case basis.
- Per UCLA policy HS 1444, ID consult is required to use this drug.

Unacceptable uses
- Infections due to non-MDR pathogens for which alternate therapy, particularly beta-lactam antibiotics, are available
- Prophylaxis

Dose
5 mg/kg/day IV divided into 2-3 doses, adjust for renal function and dialysis (see Table)
75 mg inhaled q 12 hours

Toxicity
- Renal impairment, neuromuscular blockade, neurotoxicity
- Monitor serum creatinine a minimum of twice weekly.
### Renal Function

<table>
<thead>
<tr>
<th>Renal Function</th>
<th>Loading Dose*</th>
<th>Maintenance Dose*</th>
</tr>
</thead>
<tbody>
<tr>
<td>CrCl &gt; 50 mL/min</td>
<td>5mg/kg/dose x 1dose</td>
<td>2.5 mg/kg/dose-IV Q12H</td>
</tr>
<tr>
<td>CrCl: 20-50 mL/min</td>
<td>5mg/kg/dose x 1dose</td>
<td>2.5 mg/kg/dose-IV Q24H</td>
</tr>
<tr>
<td>CrCl: &lt; 20 mL/min</td>
<td>5mg/kg/dose x 1dose</td>
<td>2.5 mg/kg/dose-IV Q48H</td>
</tr>
<tr>
<td>Intermittent hemodialysis</td>
<td>5mg/kg/dose x 1dose</td>
<td>30 mg-IV Q12H</td>
</tr>
<tr>
<td>Continuous renal replacement therapy</td>
<td>5mg/kg/dose x 1dose</td>
<td>100 mg-IV Q12H</td>
</tr>
</tbody>
</table>

*Use ideal body weight in obese patients

---

### Daptomycin

**ID consult or ASP approval is required**

Daptomycin is a lipopeptide antibiotic. It has activity against most strains of staphylococci (including MRSA) and streptococci (including VRE). It has no activity against Gram-negative organisms. Daptomycin is inactivated by pulmonary surfactant and should NOT be used in cases of documented or suspected pneumonia or other pulmonary infections.

#### Acceptable uses
- Bacteremia or endocarditis caused by MRSA or methicillin-resistant coagulase-negative staphylococci in a patient with a serious allergy to vancomycin
- Therapy for MRSA infections (other than pneumonia) in which the MIC of vancomycin is ≥2 mcg/mL
- Bacteremia or endocarditis caused by MRSA in a patient failing vancomycin therapy defined as:
  - Clinical decompensation after 3-4 days
  - Failure to clear blood cultures after 7-9 days despite therapeutic vancomycin concentrations
  - Select cases in which the MIC of vancomycin is ≥ 2 mcg/ml
- Salvage therapy for VRE infections other than pneumonia, on a case-by-case basis

#### Unacceptable uses
- Treatment of pneumonia of any kind, as daptomycin is inactivated by pulmonary surfactant.
- Initial therapy for Gram-positive infections
- VRE colonization of the urine, respiratory tract, wounds, or drains
- Convenience due to ease of dosing compared to vancomycin. Clinical pharmacists and/or the Antimicrobial Stewardship Program pharmacists are available to assist with vancomycin dosing.

#### Dose
- Bacteremia: 6-10 mg/kg IV q24h
- Endocarditis: 6-10 mg/kg IV q24h
- Dose adjustment is necessary for renal replacement therapy and CrCl < 30 ml/min

#### Toxicity
- Myopathy (defined as CK more than 10 times ULN without symptoms or more than 5 times ULN with symptoms)
Ertapenem

Ertapenem is a carbapenem antibiotic. Like the other carbapenems, ertapenem has \textit{in vitro} activity against many Gram-negative organisms including those that produce extended spectrum beta-lactamas (ESBL). Importantly, it is \textit{not} active against 	extit{P. aeruginosa} or \textit{Acinetobacter} spp. The anti-anaerobic and Gram-positive of ertapenem activity is similar to the other carbapenems; one notable exception is that it is \textit{not} active against \textit{Enterococcus} spp.

**Acceptable uses**
- Mild to moderate intra-abdominal infections (biliary tract infections, diverticulitis, secondary peritonitis/GI perforation)
- Moderate diabetic foot infections
- Moderate surgical-site infections following contaminated procedures
- Urinary tract infections caused by ESBL-producing organisms
- Pyelonephritis due to ESBL-producing organisms
- Outpatient antibiotic therapy for patients requiring IV antibiotics for polymicrobial infections caused by susceptible organisms

**Unacceptable uses**
- Infections in which \textit{Pseudomonas} spp. or \textit{Acinetobacter} spp. are suspected

**Dose**
- 1 gm IV q24h. For dialysis-dependent patients and/or those with an estimated CI\text{Cr} < 30 ml/min, use 500 mg q24.

**Toxicity**
- Diarrhea, nausea, headache, phlebitis/thrombophlebitis

Fosfomycin

Fosfomycin is a synthetic, broad-spectrum, bactericidal antibiotic with \textit{in vitro} activity against gram-negative and gram-positive organisms including \textit{E. coli}, \textit{Klebsiella} spp, \textit{Proteus} spp, and vancomycin resistant \textit{Enterococcus} (VRE). It does not have reliable activity against \textit{Pseudomonas} spp or \textit{Acinetobacter}. Fosfomycin is available in the US as an oral formulation only and its pharmacokinetics allow for one-time dosing.

**Acceptable uses**
- Management of uncomplicated UTI in patients with multiple antibiotic allergies and when oral therapy is indicated.
- Uncomplicated UTI due to VRE in patients with documented penicillin allergy.
- Salvage therapy for UTI due to multidrug-resistant organisms (e.g. ESBL, VRE, \pm \textit{Pseudomonas}) on a case by case basis.

**Unacceptable uses**
- Never use fosfomycin for management of infections outside the urinary tract because the oral formulation does not achieve adequate concentrations at other sites.

**Dose**
- Uncomplicated UTI: 3g (1 sachet) PO once.
- Complicated UTI (salvage therapy): 3g (1 sachet) PO every 3 days, up to 21 days.
Powder should be mixed with 90-120 mL of cold water, stirred to dissolve and taken immediately. May be administered with or without food.

**Toxicity**
- Diarrhea, nausea, headache, dizziness, asthenia and dyspepsia

<table>
<thead>
<tr>
<th>Organism</th>
<th>Number of isolates</th>
<th>%S*</th>
<th>%I*</th>
<th>%R*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Escherichia coli</td>
<td>700</td>
<td>90.71%</td>
<td>5%</td>
<td>4.29%</td>
</tr>
<tr>
<td>Klebsiella pneumoniae</td>
<td>197</td>
<td>81.22%</td>
<td>9.64%</td>
<td>9.14%</td>
</tr>
<tr>
<td>Klebsiella oxytoca</td>
<td>21</td>
<td>100%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Proteus mirabilis</td>
<td>66</td>
<td>89.39%</td>
<td>6.06%</td>
<td>4.55%</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>984</strong></td>
<td><strong>88.92%</strong></td>
<td><strong>5.90%</strong></td>
<td><strong>5.18%</strong></td>
</tr>
</tbody>
</table>

*Percentages calculated from AML ESBL Log
KEY: S = susceptible, I = intermediate, R = resistant

**Linezolid**

Linezolid is an oxazolidinone. It has activity against most strains of staphylococci (including MRSA), streptococci, and enterococci (including VRE). It does NOT have activity against Gram-negative organisms. It is available IV and PO and is 100% bioequivalent.

**Acceptable uses**
- Documented vancomycin-intermediate *Staphylococcus aureus* (VISA) or vancomycin-resistant *Staphylococcus aureus* (VRSA) infection.
- Documented MRSA or methicillin-resistant coagulase-negative staphylococcal infection in a patient with a severe allergy to vancomycin.
- Documented MRSA or methicillin-resistant coagulase-negative staphylococcal infection in a patient failing vancomycin therapy despite appropriate levels.
- Bacteremia/endocarditis: failure to clear blood cultures after 7-9 days despite vancomycin troughs of 15-20 mcg/mL or in a patient with a MRSA isolate with a MIC ≥ 2 mcg/ml. Should be used in combination with another agent as linezolid is bacteriostatic, not bactericidal.
- Pneumonia: worsening infiltrate or pulmonary status in a patient with documented MRSA pneumonia after 2-3 days of vancomycin therapy or if the MIC of vancomycin is ≥ 2 mcg/mL. ID consultation strongly advised.
- High suspicion of CA-MRSA necrotizing pneumonia in a critically-ill patient.
- Documented VRE infection (not colonization).
- Post-neurosurgical shunt infection, meningitis or ventriculitis due to *Staphylococcal spp* or VRE.
- Gram-positive cocci in chains in a blood culture in an ICU, solid oncology, or transplant patient known to be colonized with VRE.
- Treatment of atypical mycobacterial or nocardial infections on a case by case basis. ID consultation strongly advised.

**Unacceptable uses**
- Prophylaxis.
- Initial therapy for staphylococcal infection.
- VRE colonization of the stool, urine, respiratory tract, wounds, or drains
Dose
- 600 mg IV/PO q12h

Toxicity
- Bone marrow suppression (usually occurs after 10-14 days of therapy). Pyridoxine is of no benefit.
- Optic neuritis and irreversible sensory motor polyneuropathy (usually occurs with prolonged therapy >28 days)
- Lactic acidosis (case reports)
- Serotonin syndrome when co-administered with serotonergic agents e.g. SSRIs, SNRIs, TCAs, MAOIs (case reports)
- Monitoring: CBC weekly, consider periodic LFTs with prolonged use.

Tigecycline
ID consult or ASP approval is required

Tigecycline is a tetracycline derivative. It has in vitro activity against most strains of staphylococci, streptococci, and enterococci (including MRSA and VRE), anaerobes, and many gram-negative organisms with the exception of Pseudomonas, Proteus, and Providencia. It is FDA-approved for treatment of skin and skin-structure infections and intraabdominal infections. Tigecycline distributes extensively into tissues resulting in low peak serum concentrations, which limits its use for treatment of bloodstream infections.

FDA Black Box Warning [updated 9/2013]: Increased mortality risk associated with the use of the intravenous Tygacil (tigecycline) compared to that of other drugs used to treat a variety of serious infections: http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm

Acceptable uses
- Management of intra-abdominal infections in patients with contraindications to both beta-lactams and fluoroquinolones.
- Management of infections due to multidrug resistant Gram-negative organisms including Acinetobacter on a case by case basis.
- Salvage therapy for MRSA or VRE infections on a case by case basis.

Unacceptable use
- Bacteremia and endocarditis.
- Tigecycline should not be used to treat pneumonia as unacceptably high failure rates have been reported (see black box warning).

Dose
- Usual dose: 100 mg IV once, then 50 mg IV q12h
- Severe hepatic impairment (Child Pugh Class C): 100 mg IV once, then 25 mg IV q12h

Toxicity
- Severe nausea/vomiting (most common), diarrhea (including C. difficile), abdominal pain, elevated liver transaminases, pancreatitis (acute)
- Monitoring: LFTs weekly
Vancomycin

At UCLA in 2014, 33% of all S. aureus isolates were resistant to oxacillin. These data suggest that empiric use of vancomycin is advisable for an ill patient with suspected S. aureus infection. However, vancomycin should be stopped if culture data do not indicate a need for continued definitive therapy (see below). **Limiting prolonged or inappropriate use of vancomycin is essential.** Presently vancomycin is the most highly utilized antibiotic at UCLA, with approximately 15% of all inpatients receiving at least one day of therapy. There are few instances when continued use of vancomycin is appropriate in the absence of positive cultures. The following are recommendations for empiric, definitive, and prophylactic vancomycin therapy.

**Acceptable Empiric Use**

- Treatment of suspected community- or nosocomial-acquired bacterial meningitis.
- Treatment of healthcare-associated (including ventilator-associated) pneumonia.
- Treatment of peritoneal dialysis-related peritonitis in a severely ill patient.
- Treatment of sepsis in a patient at risk for MRSA bacteremia [catheter in place, indwelling hardware, known MRSA colonization, transfer from a nursing home or subacute facility, recent (within 3 months) or current prolonged hospitalization >2 weeks, hemodialysis].
- Treatment of surgical-site infection following placement of hardware.
- Treatment of severe diabetic foot infection in a patient at risk for MRSA.
- Treatment of necrotizing fasciitis.
- Treatment of suspected endocarditis in a moderately or severely ill patient **after** appropriate blood cultures are obtained.
- Treatment of Gram-positive cocci in clusters in ≥ 1 set of blood cultures in a moderately or severely ill patient.
- Treatment of Gram-positive cocci in clusters or chains in ≥ 2 sets of blood cultures in any patient.

Note: empiric therapy should be **discontinued** within 72 hours if criteria for definitive therapy (listed below) are **not** met:

**Acceptable Use for Definitive Intravenous Therapy**

- Proven infection with beta-lactam resistant organisms:
  - MRSA
  - Methicillin-resistant coagulase-negative staphylococcus
  - Ampicillin-resistant enterococcus (if susceptible)
  - Ceftriaxone-resistant S. pneumoniae (CSF only)
- Treatment of infections caused by Gram-positive organisms in patients who have severe allergic reactions to beta-lactam antibiotics (see discussion of penicillin allergy).

**Acceptable Use for Definitive Oral Therapy**

- *Clostridium difficile* infection (see CDI section)

**Acceptable Use for Prophylaxis**

- Prophylaxis for cardiac, vascular, or orthopedic (joint replacement, spinal fusion, ORIF only) surgery with a documented reason in the chart or in patients with severe beta-lactam allergy (no more than one pre-op and one post-op dose).
Unacceptable Uses for Vancomycin

- Continued empiric use for presumed infection with negative cultures.
- Treatment of a single-positive blood culture for coagulase-negative staphylococci.
- Routine surgical prophylaxis except as above.
- Empiric treatment for first fever in neutropenic patients without evidence of catheter-related bloodstream infection (e.g. inflamed IV catheter site), severe mucositis, or history of MRSA.
- Prophylaxis for infection or colonization of indwelling intravascular or intracranial catheters.
- Selective decontamination of the digestive tract.
- Eradication of MRSA colonization.
- Routine prophylaxis for patients on continuous ambulatory peritoneal dialysis or hemodialysis.
- When chosen only for convenience of dosing for treatment of infections caused by beta-lactam susceptible organisms in patients who are HD-dependent.
- Topical application or irrigation.

Dosing

- Round dose to nearest 250mg increment
- Maximum: 2 gram/dose
- Trough levels should be obtained within 30 minutes before the 4th dose for a new regimen or dose change. Vancomycin troughs are not recommended if anticipated duration of therapy is ≤ 3 days.
- Goal trough concentrations:
  - Uncomplicated infections: skin/soft tissue infections, UTI: 10-15 mcg/mL.
  - Serious/Severe infections* (meningitis, endocarditis, BSI, PNA, osteo): 15-20 mcg/mL.

<table>
<thead>
<tr>
<th>Renal Function</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>CrCl &gt;60mL/min</td>
<td><strong>Uncomplicated Infections</strong></td>
</tr>
<tr>
<td></td>
<td>10-15mg/kg IV Q12h</td>
</tr>
<tr>
<td></td>
<td><strong>Serious/Severe Infections</strong></td>
</tr>
<tr>
<td></td>
<td>Consider <em>loading dose of 25mg/kg</em> IV x1</td>
</tr>
<tr>
<td></td>
<td>followed by 15-20mg/kg IV Q8-12h</td>
</tr>
<tr>
<td>CrCl: 40-60 mL/min</td>
<td>10-15mg/kg IV Q12h-Q24h</td>
</tr>
<tr>
<td>CrCl: 20-40mL/min</td>
<td>5-10mg/kg IV Q24h</td>
</tr>
<tr>
<td>CrCl: 10-20 mL/min</td>
<td>5-10mg/kg IV Q24h-Q48h</td>
</tr>
<tr>
<td>CrCl: &lt;10 mL/min</td>
<td>10-15mg/kg IV loading dose x1, then</td>
</tr>
<tr>
<td></td>
<td>redoses according to levels</td>
</tr>
<tr>
<td>Intermittent hemodialysis</td>
<td>15-20mg/kg loading dose x1 followed by 0.5-1g PHD only</td>
</tr>
<tr>
<td>Continuous renal replacement therapy</td>
<td>10-15mg/kg IV Q24h</td>
</tr>
</tbody>
</table>

*ID consultation recommended

KEY: BSI: bloodstream infection, PNA: pneumonia, UTI: urinary tract infection